Lymphoma patients treated with anti-CD20 and chemotherapy display disconnected T and B cell responses to COVID-19 vaccine.

Fiche publication

Date publication

janvier 2025

Journal

Frontiers in immunology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr FORNECKER Luc-Matthieu , Dr DRENOU Bernard

Tous les auteurs :
Lamure S, Chavez HH, de Goër de Herve MG, Fornecker LM, Drenou B, Jacquet C, Merabet F, Kohn M, Quélin F, Jackson A, Choquet S, Duléry R, Taoufik Y, Besson C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39902042

Résumé

Due to immunosuppressive treatment, COVID-19 vaccination is challenging in patients with B-cell lymphoma. We prospectively evaluated CD4, CD8 T-cell and serological responses to the COVID-19 mRNA vaccine in a cohort of patients treated for a B-cell lymphoma with anti-CD20 therapy. During lymphoma treatment, CD4, CD8, and CD19 cell dropped. While functional-specific CD4 and CD8 T-cell responses to SARS-CoV-2 were unaffected, vaccination in patients on treatment induced low specific antibody titers, contrasting with a preserved serological response when vaccination was completed before treatment initiation. Those findings reinforce a vaccinal strategy based on completion before lymphoma treatment, with a booster administered afterward.